Compared with placebo, fremanezumab significantly reduced both monthly migraine days and depressive symptoms in patients with migraine and moderate to severe comorbid MDD, according to a study published in JAMA Neurology.
Compared with placebo, fremanezumab significantly reduced both monthly migraine days and depressive symptoms in patients with migraine and moderate to severe comorbid MDD, according to a study published in JAMA Neurology.
Compared with placebo,...